Background Aging is a critical risk factor for the progression and complications of type 2 diabetes mellitus (T2DM). However, routine clinical indicators fail to accurately quantify biological senescence burden in T2DM patients. This study aimed to screen plasma protein signatures associated with metabolic senescence in T2DM using Olink targeted proteomics and to construct a novel biological aging evaluation model for diabetic populations. Methods A total of 21 healthy controls and 66 T2DM patients were enrolled. Plasma protein profiles were detected via Olink proteomics. Differentially expressed proteins (DEPs) were identified and subjected to GO and KEGG functional enrichment analyses. Random forest and LASSO regression analyses were applied to screen core T2DM-related protein molecules. T2DM patients were further stratified by a 55-year cutoff, a well-recognized critical threshold for metabolic senescence. After adjustment for sex, BMI, glycated hemoglobin (HbA1C), and hypoglycemic medication use, age-independent senescence-related proteins were identified to establish a multi-protein predictive model. A 1000-time Bootstrap resampling procedure was performed for internal validation to evaluate model discrimination and stability. Results A total of 84 DEPs (P < 0.05) were identified between T2DM patients and healthy controls, mainly enriched in cytokine–cytokine receptor interaction, lipid metabolism, and atherosclerosis pathways. Machine learning screened six core proteins with high discriminatory value for T2DM, including MERTK, BOC, TNFRSF10A, CCL3, AGRP, and PD-L2. Within the T2DM cohort, nine age-dependent plasma proteins were independently identified (FDR < 0.05), among which VSIG2, LPL, S100A11, and CST5 exhibited the most robust correlations (FDR < 0.01). A three-protein model comprising VSIG2, S100A11, and S100A5 achieved favorable discriminative performance (AUC = 0.874), which was superior to conventional clinical indicators including BMI (AUC = 0.572) and HbA1c (AUC = 0.593). Bootstrap validation confirmed reliable model stability with a correction optimism of −0.024, a bias-corrected AUC of 0.900, and an overfitting degree of −2.65%. Functional analyses indicated that candidate proteins were primarily involved in immune homeostasis, lipid remodeling, inflammatory responses, and calcium signaling. Conclusion This study identified novel T2DM-associated plasma biomarkers and established a robust three-protein signature (VSIG2, S100A11, S100A5) for age stratification and biological senescence evaluation in T2DM. The proposed model compensates for the limitations of routine clinical indices, providing a promising non-invasive serological tool for precise risk stratification and individualized intervention in elderly diabetic patients.
Yan Yang, Shi-Yu Liu, Chun-Guang Xie et al.· Frontiers in Endocrinology· 0 citations
Fibrosis is the outcome of chronic diseases and manifests as an abnormal repair process in which normal parenchyma is progressively replaced by deposited extracellular matrix. It leads to organ dysfunction and is associated with high morbidity, disability, and mortality, thereby becoming a major public health concern. Traditional Chinese medicine shows multi-target, multi-pathway strategies with favorable safety profiles. Curcumin (CUR), a polyphenolic metabolite derived from Curcuma longa L. (Zingiberaceae), has been shown to modulate key fibrotic signaling pathways, including AMPK, autophagy, extracellular-regulated protein kinase (ERK), transforming growth factor β (TGF-β)/Smad, JNK, and Wnt/β-catenin. However, a critical analysis of more than 200 included studies reveals that the current evidence base is fundamentally descriptive rather than conclusive. The data show reproducible antifibrotic signals in acute chemical injury models (bleomycin (BLM), carbon tetrachloride (CCl4), and streptozotocin (STZ) when CUR is administered prophylactically. The data do not show (1) efficacy in chronic, progressive disease models that recapitulate human pathology; (2) a dose-response relationship linking achievable tissue concentrations to antifibrotic effects; (3) superiority over or an add-on benefit to standard-of-care antifibrotics; or (4) robust clinical efficacy beyond small, uncontrolled case series. Despite this promising preclinical evidence supporting CUR's antifibrotic efficacy, clinical translation remains constrained by several critical limitations. The majority of evidence derives from in vitro studies using supraphysiological concentrations that far exceed achievable human plasma levels and from animal models that incompletely recapitulate the chronic, progressive nature of human fibrotic diseases. Additionally, the inherently poor oral bioavailability of CUR-despite advances in formulation strategies-remains a persistent obstacle. A critical appraisal of the existing literature further reveals substantial heterogeneity in experimental designs, a predominance of positive results suggestive of publication bias, and insufficient mechanistic validation to establish causality. This review outlines the mechanisms of action, safety, adverse effects, drug interactions, and the application of CUR-related nanocomposite products, thereby providing a foundation for in-depth research on its antifibrotic properties and clinical application.
Ting Luo, Jia Gao, Qingzhi Liang et al.· Frontiers in Pharmacology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.